Meeting
2023 ASCO Annual Meeting
The effect of a reduced dose of enzalutamide on fatigue and cognition.
Authors
Joanneke Overbeek
Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands
Joanneke Overbeek , Emmy Boerrigter , Guillemette Emma Benoist , Diederik Meindert Somford , Paul Hamberg , Jolien Tol , Brian Scholtes , Annelieke E.C.A.B. Willemsen , Laurien M Buffart , Roy P.C. Kessels , Niven Mehra , Inge M. van Oort , Nielka P. Van Erp
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03927391
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5051)
DOI
10.1200/JCO.2023.41.16_suppl.5051
Abstract #
5051
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.
First Author: Bobby Chi-Hung Liaw
Poster
2022 ASCO Annual Meeting
Feasibility of a novel wrist-worn thermal device for management of vasomotor symptoms in patients with prostate cancer.
First Author: Alicia K. Morgans
Poster
2018 Genitourinary Cancers Symposium
Niclosamide in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC): initial results from a phase Ib/II trial.
First Author: Chong-xian Pan
Poster
2017 Genitourinary Cancers Symposium
Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results.
First Author: Bertrand F. Tombal